Rahul Gosain, Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, shared a post on LinkedIn:
“GISeries: Zanidatamab was recently approved based off HerizonBTC01!
We spoke design, findings, sequencing and AEs/management with Shubham Pant.
Full Discussion here.”